anurajms/meta_analysis huggingface dataset:
MESH terms:
Methods for managing miscarriage: a network meta‐analysis
1. Abortion, Incomplete [therapy]; 2. Abortion, Missed [therapy]; 3. Abortion, Spontaneous [*therapy]; 4. Drug Therapy, Combination; 5. Mifepristone [administration & dosage]; 6. Misoprostol [administration & dosage]; 7. Network Meta-Analysis; 8. Oxytocics [administration & dosage]; 9. Placebos [administration & dosage]; 10. *Pregnancy Trimester, First; 11. Randomized Controlled Trials as Topic; 12. Suction [statistics & numerical data]; 13. Vacuum Curettage [statistics & numerical data]; 14. Watchful Waiting [statistics & numerical data];
MESH terms:
Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section
1. Acupressure; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Anesthesia, Conduction [*adverse effects]; 4. Bias; 5. *Cesarean Section; 6. Dopamine Antagonists [therapeutic use]; 7. Elective Surgical Procedures; 8. Hypnotics and Sedatives [therapeutic use]; 9. Intraoperative Complications [*prevention & control]; 10. Nausea [*prevention & control]; 11. Postoperative Nausea and Vomiting [prevention & control]; 12. Pregnancy Complications [*prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Serotonin Antagonists [therapeutic use]; 15. Vomiting [*prevention & control];
MESH terms:
Umbilical vein injection for management of retained placenta
1. Anti-Bacterial Agents [therapeutic use]; 2. Bias; 3. Blood Transfusion [statistics & numerical data]; 4. Injections, Intravenous; 5. Oxytocics [*administration & dosage]; 6. Oxytocin [*administration & dosage]; 7. Placenta, Retained [*therapy]; 8. Plasma Substitutes [administration & dosage]; 9. Prostaglandins [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Sodium Chloride [administration & dosage]; 12. Umbilical Veins;
MESH terms:
Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period
1. Acetaminophen [administration & dosage]; 2. Administration, Oral; 3. Analgesia; 4. Analgesics, Non-Narcotic [administration & dosage]; 5. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage, adverse effects]; 6. Neuralgia [*drug therapy]; 7. Perineum [*injuries]; 8. *Postpartum Period; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period
1. *Acetaminophen; 2. *Acute Pain; 3. Episiotomy; 4. Perineum; 5. Postpartum Period;
MESH terms:
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
1. Adrenal Cortex Hormones [*administration & dosage]; 2. Betamethasone [administration & dosage]; 3. Bias; 4. Cerebral Intraventricular Hemorrhage [prevention & control]; 5. Developmental Disabilities [epidemiology]; 6. Dexamethasone [administration & dosage]; 7. Fetal Organ Maturity [*drug effects]; 8. Hydrocortisone [administration & dosage]; 9. Lung [drug effects, *embryology]; 10. Maternal Death; 11. Perinatal Death; 12. *Premature Birth; 13. Prenatal Care [*methods]; 14. Randomized Controlled Trials as Topic; 15. Respiratory Distress Syndrome, Newborn [*prevention & control];
MESH terms:
Multi‐professional simulation‐based team training in obstetric emergencies for improving patient outcomes and trainees' performance
1. Apgar Score; 2. Bias; 3. Cesarean Section [statistics & numerical data]; 4. Clinical Competence; 5. Confidence Intervals; 6. Emergencies; 7. Infant Mortality; 8. Maternal Mortality; 9. Medical Errors [prevention & control]; 10. Obstetrics [*education]; 11. Patient Care Team [*organization & administration]; 12. Randomized Controlled Trials as Topic; 13. Shoulder Dystocia [epidemiology]; 14. Simulation Training [*methods]; 15. Treatment Outcome;
MESH terms:
Uterotonic agents for first‐line treatment of postpartum haemorrhage: a network meta‐analysis
1. Bias; 2. Blood Transfusion [statistics & numerical data]; 3. Confidence Intervals; 4. Drug Therapy, Combination [methods]; 5. Ergonovine [*therapeutic use]; 6. Misoprostol [adverse effects, *therapeutic use]; 7. *Network Meta-Analysis; 8. Oxytocics [adverse effects, *therapeutic use]; 9. Oxytocin [adverse effects, *therapeutic use]; 10. Postpartum Hemorrhage [chemically induced, *drug therapy, mortality]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour
1. Bias; 2. Blood Transfusion [statistics & numerical data]; 3. Confidence Intervals; 4. Injections, Intramuscular; 5. Injections, Intravenous; 6. *Labor Stage, Third; 7. Oxytocics [*administration & dosage, adverse effects]; 8. Oxytocin [*administration & dosage, adverse effects]; 9. Postpartum Hemorrhage [epidemiology, *prevention & control]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Maintenance agonist treatments for opiate‐dependent pregnant women
1. Birth Weight [drug effects]; 2. Buprenorphine [adverse effects, therapeutic use]; 3. Delayed-Action Preparations [adverse effects, therapeutic use]; 4. Methadone [adverse effects, therapeutic use]; 5. Morphine [adverse effects, therapeutic use]; 6. Narcotics [adverse effects, agonists, *therapeutic use]; 7. *Opiate Substitution Treatment; 8. Opioid-Related Disorders [*rehabilitation]; 9. Patient Dropouts [statistics & numerical data]; 10. Pregnancy Complications [*rehabilitation]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing mastitis after childbirth
1. Anti-Bacterial Agents [*administration & dosage]; 2. Bias; 3. Breast Feeding [*adverse effects]; 4. Edible Grain [chemistry]; 5. Fusidic Acid [administration & dosage]; 6. Massage [methods]; 7. Mastitis [*prevention & control]; 8. Mupirocin [administration & dosage]; 9. Neuropeptides [administration & dosage]; 10. Ointments [administration & dosage]; 11. *Patient Education as Topic; 12. Placebos [therapeutic use]; 13. Probiotics [therapeutic use]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies
1. Albuterol [therapeutic use]; 2. Analgesics, Opioid [therapeutic use]; 3. Anti-Bacterial Agents [therapeutic use]; 4. Bias; 5. Cefazolin [therapeutic use]; 6. Cerclage, Cervical [*methods]; 7. Clindamycin [therapeutic use]; 8. Indomethacin [therapeutic use]; 9. Opium [therapeutic use]; 10. Premature Birth [epidemiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Stillbirth [epidemiology]; 13. Tocolytic Agents [therapeutic use];
MESH terms:
Home versus inpatient induction of labour for improving birth outcomes
1. Ambulatory Care [*methods]; 2. Catheterization [methods]; 3. *Cervical Ripening; 4. Cesarean Section [statistics & numerical data]; 5. Delayed-Action Preparations; 6. Dinoprostone; 7. *Hospitalization; 8. Labor, Induced [*methods]; 9. Length of Stay; 10. Oxytocics; 11. Patient Safety; 12. Patient Satisfaction; 13. Pregnancy Outcome; 14. Randomized Controlled Trials as Topic;
MESH terms:
Aspirin (single dose) for perineal pain in the early postpartum period
1. Acute Pain [*drug therapy]; 2. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage]; 3. Aspirin [*administration & dosage]; 4. Episiotomy [adverse effects]; 5. Obstetric Labor Complications [*drug therapy]; 6. Pain, Postoperative [drug therapy]; 7. *Perineum; 8. Placebo Effect; 9. Postpartum Period; 10. Randomized Controlled Trials as Topic; 11. Time Factors;
MESH terms:
Induction of labour at or beyond 37 weeks' gestation
1. Cesarean Section [statistics & numerical data]; 2. Gestational Age; 3. Infant Mortality; 4. Intensive Care Units, Neonatal [statistics & numerical data]; 5. Labor, Induced [*adverse effects]; 6. Perinatal Death; 7. *Pregnancy, Prolonged; 8. Randomized Controlled Trials as Topic; 9. Risk; 10. Stillbirth [epidemiology]; 11. *Watchful Waiting;
MESH terms:
Techniques for preventing hypotension during spinal anaesthesia for caesarean section
1. Anesthesia, Obstetrical [*adverse effects]; 2. Anesthesia, Spinal [*adverse effects]; 3. Antiemetics [therapeutic use]; 4. *Cesarean Section; 5. Colloids [therapeutic use]; 6. Crystalloid Solutions [therapeutic use]; 7. Ephedrine [therapeutic use]; 8. Hypotension [chemically induced, *prevention & control]; 9. Intraoperative Complications [*prevention & control]; 10. Isotonic Solutions [therapeutic use]; 11. Ondansetron [therapeutic use]; 12. Phenylephrine [therapeutic use]; 13. Postoperative Nausea and Vomiting [drug therapy]; 14. Randomized Controlled Trials as Topic; 15. Vasoconstrictor Agents [therapeutic use]; 16. Walking;
MESH terms:
Mechanical and surgical interventions for treating primary postpartum haemorrhage
1. Bias; 2. Blood Transfusion [statistics & numerical data]; 3. Hemostasis, Surgical [methods]; 4. Hemostatic Techniques; 5. Hysterectomy [methods]; 6. Postpartum Hemorrhage [*therapy]; 7. Pressure; 8. Randomized Controlled Trials as Topic; 9. Suture Techniques; 10. Uterine Artery Embolization; 11. Uterine Balloon Tamponade [methods];
MESH terms:
Skin preparation for preventing infection following caesarean section
1. Anti-Infective Agents, Local [adverse effects, *therapeutic use]; 2. Bandages; 3. Cesarean Section [*adverse effects]; 4. Chlorhexidine [adverse effects, analogs & derivatives, therapeutic use]; 5. Endometritis [epidemiology, *prevention & control]; 6. Ethanol [therapeutic use]; 7. Iodine [therapeutic use]; 8. Iodophors [therapeutic use]; 9. Length of Stay; 10. Povidone-Iodine [adverse effects, therapeutic use]; 11. Preoperative Care [*methods]; 12. Randomized Controlled Trials as Topic; 13. *Surgical Drapes; 14. Surgical Wound Infection [epidemiology, *prevention & control]; 15. Xylenes [therapeutic use];
MESH terms:
Advance misoprostol distribution to pregnant women for preventing and treating postpartum haemorrhage
1. Misoprostol [*supply & distribution]; 2. Oxytocics [*supply & distribution]; 3. Postpartum Hemorrhage [*prevention & control];
MESH terms:
Anaesthesia/analgesia for manual removal of retained placenta
1. *Analgesia, Obstetrical; 2. *Anesthesia, Obstetrical; 3. Job Satisfaction; 4. Nerve Block [*methods]; 5. Pain, Procedural [*prevention & control]; 6. Patient Satisfaction [statistics & numerical data]; 7. Placenta, Retained [*surgery];
MESH terms:
Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm birth
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Developed Countries; 3. Developing Countries; 4. Inappropriate Prescribing; 5. Infant, Premature; 6. Perinatal Death; 7. *Premature Birth; 8. Randomized Controlled Trials as Topic; 9. Stillbirth [epidemiology];
MESH terms:
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1. Abortion, Habitual [blood, *prevention & control]; 2. Antibodies, Anticardiolipin [blood]; 3. Antibodies, Antiphospholipid [*blood]; 4. Anticoagulants [adverse effects, *therapeutic use]; 5. Aspirin [adverse effects, *therapeutic use]; 6. beta 2-Glycoprotein I [immunology]; 7. Bias; 8. Drug Therapy, Combination; 9. Heparin [adverse effects, *therapeutic use]; 10. Heparin, Low-Molecular-Weight [therapeutic use]; 11. Live Birth; 12. Lupus Coagulation Inhibitor [blood]; 13. Placebos [therapeutic use]; 14. Pre-Eclampsia [prevention & control]; 15. Pregnancy Complications, Hematologic [chemically induced]; 16. *Pregnancy Outcome; 17. Randomized Controlled Trials as Topic;
MESH terms:
Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
1. Administration, Intravaginal; 2. Anti-Infective Agents, Local [*administration & dosage]; 3. Benzalkonium Compounds [administration & dosage]; 4. Cesarean Section [*adverse effects]; 5. Chlorhexidine [administration & dosage]; 6. Disinfection [*methods]; 7. Endometritis [*prevention & control]; 8. Fever [prevention & control]; 9. Povidone-Iodine [administration & dosage]; 10. Preoperative Care [*methods]; 11. Randomized Controlled Trials as Topic; 12. Surgical Wound Infection [*prevention & control];
MESH terms:
Antibiotic prophylaxis for operative vaginal delivery
1. *Antibiotic Prophylaxis [adverse effects]; 2. Amoxicillin‐Potassium Clavulanate Combination [therapeutic use]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Cefotetan [therapeutic use]; 5. Endometritis [prevention & control]; 6. Episiotomy [adverse effects]; 7. Extraction, Obstetrical [*adverse effects]; 8. Length of Stay; 9. Obstetrical Forceps; 10. Perineum [injuries]; 11. Puerperal Infection [*prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Surgical Wound Infection [prevention & control]; 14. Vacuum Extraction, Obstetrical [adverse effects]; 15. Vaginal Diseases [*prevention & control];
MESH terms:
Pharmacological interventions for promoting smoking cessation during pregnancy
1. Bupropion [therapeutic use]; 2. Nicotinic Agonists [therapeutic use]; 3. Pregnancy Complications [*prevention & control]; 4. Pregnancy Outcome; 5. Randomized Controlled Trials as Topic; 6. Smoking [*therapy]; 7. *Smoking Cessation [methods]; 8. Tobacco Use Cessation Devices;
MESH terms:
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
1. Abortion, Habitual [*etiology, prevention & control]; 2. Abortion, Spontaneous [prevention & control]; 3. Pregnancy Trimester, First; 4. Pregnancy Trimester, Second; 5. Premature Birth [prevention & control]; 6. Progesterone [deficiency, *metabolism]; 7. Progestins [*therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Antiplatelet agents for preventing pre‐eclampsia and its complications
1. Aspirin [therapeutic use]; 2. Gestational Age; 3. Infant, Small for Gestational Age; 4. Maternal Mortality; 5. Platelet Aggregation Inhibitors [*therapeutic use]; 6. Pre‐Eclampsia [drug therapy, *prevention & control]; 7. Premature Birth [prevention & control]; 8. Prenatal Care [*methods]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Cervical assessment by ultrasound for preventing preterm delivery
1. Cervical Length Measurement [*methods]; 2. Cervix Uteri [*diagnostic imaging]; 3. Obstetric Labor, Premature [*prevention & control]; 4. Pregnancy, Multiple; 5. Pregnancy, Twin; 6. Premature Birth [diagnostic imaging, *prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for supporting the initiation and continuation of breastfeeding among women who are overweight or obese
1. Breast Feeding [*psychology]; 2. Health Promotion [*methods]; 3. Mothers [education, *psychology]; 4. *Obesity [prevention & control]; 5. *Overweight [prevention & control]; 6. Postpartum Period; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes
1. *Infant, Premature [growth & development]; 2. *Umbilical Cord; 3. Blood Transfusion [statistics & numerical data]; 4. Cerebral Hemorrhage [prevention & control]; 5. Delivery, Obstetric; 6. Placental Circulation [*physiology]; 7. Pregnancy Outcome; 8. Premature Birth; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Fetal fibronectin testing for reducing the risk of preterm birth
1. Biomarkers [analysis]; 2. Fibronectins [analysis, *therapeutic use]; 3. Gestational Age; 4. Obstetric Labor, Premature [*prevention & control]; 5. Premature Birth [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Respiratory Distress Syndrome, Newborn [prevention & control];
MESH terms:
Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
1. Blood Transfusion [statistics & numerical data]; 2. Delivery, Obstetric; 3. *Labor Stage, Third; 4. Odds Ratio; 5. Oxytocin [*administration & dosage]; 6. Postpartum Hemorrhage [*prevention & control];
MESH terms:
Active versus expectant management for women in the third stage of labour
1. *Watchful Waiting; 2. Birth Weight; 3. Constriction; 4. Delivery, Obstetric [adverse effects, *methods]; 5. Jaundice, Neonatal [therapy]; 6. Labor Stage, Third [*physiology]; 7. Oxytocics [*administration & dosage, adverse effects]; 8. Placenta; 9. Postpartum Hemorrhage [*prevention & control]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis
1. *Network Meta‐Analysis; 2. Drug Therapy, Combination [adverse effects, methods]; 3. Ergonovine [adverse effects, *therapeutic use]; 4. Fever [chemically induced]; 5. Hypertension [chemically induced]; 6. Misoprostol [*therapeutic use]; 7. Oxytocics [*therapeutic use]; 8. Oxytocin [adverse effects, *analogs & derivatives, *therapeutic use]; 9. Postpartum Hemorrhage [*prevention & control]; 10. Prostaglandins [*therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Vomiting [chemically induced];
MESH terms:
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
1. Aspirin [administration & dosage, *therapeutic use]; 2. Fibrinolytic Agents [administration & dosage, *therapeutic use]; 3. Heparin, Low-Molecular-Weight [*therapeutic use]; 4. Parents; 5. Perinatal Mortality; 6. Prenatal Care [*methods]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Secondary Prevention [*methods]; 10. *Stillbirth [epidemiology];
MESH terms:
Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation
1. *Delivery, Obstetric [adverse effects, methods]; 2. *Watchful Waiting; 3. Cerebral Hemorrhage [epidemiology]; 4. Cesarean Section [statistics & numerical data]; 5. Eclampsia [epidemiology]; 6. Enterocolitis, Necrotizing [etiology]; 7. HELLP Syndrome [epidemiology]; 8. Hyaline Membrane Disease [etiology]; 9. Perinatal Mortality; 10. Pre‐Eclampsia [*therapy]; 11. Pulmonary Edema [epidemiology]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Methods for blood loss estimation after vaginal birth
1. Blood Specimen Collection [*methods]; 2. Blood Transfusion [statistics & numerical data]; 3. Labor Stage, Third [*blood]; 4. Oxytocics [administration & dosage]; 5. Plasma Substitutes [administration & dosage]; 6. Postpartum Hemorrhage [*blood]; 7. Randomized Controlled Trials as Topic; 8. Surgical Drapes;
MESH terms:
Discontinuation of intravenous oxytocin in the active phase of induced labour
1. Administration, Intravenous; 2. Cardiotocography; 3. Cesarean Section [statistics & numerical data]; 4. Chorioamnionitis [etiology]; 5. Fetal Distress [prevention & control]; 6. Intention to Treat Analysis; 7. Labor Stage, Third [physiology]; 8. *Labor, Induced; 9. Oxytocics [*administration & dosage, adverse effects]; 10. Oxytocin [*administration & dosage, adverse effects]; 11. Randomized Controlled Trials as Topic; 12. *Withholding Treatment;
MESH terms:
Progestogen for treating threatened miscarriage
1. Abortion, Spontaneous [epidemiology]; 2. Abortion, Threatened [*drug therapy]; 3. Administration, Intravaginal; 4. Congenital Abnormalities [epidemiology]; 5. Premature Birth [drug therapy, epidemiology, prevention & control]; 6. Progestins [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Acute tocolysis for uterine tachysystole or suspected fetal distress
1. Adrenergic beta‐2 Receptor Agonists [therapeutic use]; 2. Cesarean Section [statistics & numerical data]; 3. Fenoterol [therapeutic use]; 4. Fetal Distress [*drug therapy]; 5. Hexoprenaline [therapeutic use]; 6. Nitroglycerin [therapeutic use]; 7. Perinatal Death; 8. Randomized Controlled Trials as Topic; 9. Terbutaline [therapeutic use]; 10. Tocolysis [*methods]; 11. Tocolytic Agents [*therapeutic use]; 12. Uterine Contraction [*drug effects]; 13. Vasotocin [analogs & derivatives, therapeutic use];
MESH terms:
Parenteral opioids for maternal pain management in labour
1. Analgesia, Obstetrical [*methods]; 2. Analgesics, Opioid [*administration & dosage, adverse effects]; 3. Injections, Intramuscular; 4. Injections, Intravenous; 5. Labor Pain [*drug therapy]; 6. Meperidine [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Transcutaneous Electric Nerve Stimulation;
MESH terms:
Interventions for investigating and identifying the causes of stillbirth
1. *Stillbirth; 2. Cause of Death;
MESH terms:
Antifibrinolytic drugs for treating primary postpartum haemorrhage
1. Antifibrinolytic Agents [administration & dosage, *therapeutic use]; 2. Cause of Death; 3. Maternal Mortality; 4. Misoprostol [administration & dosage, *therapeutic use]; 5. Postpartum Hemorrhage [*drug therapy, mortality]; 6. Randomized Controlled Trials as Topic; 7. Tranexamic Acid [administration & dosage, *therapeutic use];
MESH terms:
Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
1. Cesarean Section; 2. *Diabetes, Gestational; 3. Fetal Macrosomia [*prevention & control]; 4. Labor, Induced [*methods]; 5. *Term Birth; 6. *Watchful Waiting;
MESH terms:
Antenatal maternal education for improving postnatal perineal healing for women who have birthed in a hospital setting
1. *Postnatal Care; 2. *Wound Healing; 3. Mothers [*education]; 4. Perineum [*injuries]; 5. Prenatal Care [*methods];
MESH terms:
Regimens of ultrasound surveillance for twin pregnancies for improving outcomes
1. *Fetal Development; 2. *Pregnancy, Twin; 3. *Ultrasonography, Prenatal; 4. Perinatal Death; 5. Perinatal Mortality; 6. Pregnancy Outcome; 7. Stillbirth;
MESH terms:
Antibiotic prophylaxis for episiotomy repair following vaginal birth
1. *Antibiotic Prophylaxis; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Chloramphenicol [*therapeutic use]; 4. Episiotomy [*adverse effects]; 5. Parturition; 6. Surgical Wound Dehiscence [epidemiology, *prevention & control]; 7. Surgical Wound Infection [epidemiology, *prevention & control];
MESH terms:
Interventions for treating genital Chlamydia trachomatis infection in pregnancy
1. *Chlamydia trachomatis; 2. Amoxicillin [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Azithromycin [therapeutic use]; 5. Chlamydia Infections [*drug therapy]; 6. Clindamycin [therapeutic use]; 7. Erythromycin [therapeutic use]; 8. Pregnancy Complications, Infectious [*drug therapy, microbiology]; 9. Randomized Controlled Trials as Topic; 10. Reproductive Tract Infections [*drug therapy];
MESH terms:
Amniocentesis and chorionic villus sampling for prenatal diagnosis
1. Amniocentesis [*adverse effects, standards]; 2. Chorionic Villi Sampling [*adverse effects, standards]; 3. Congenital Abnormalities [diagnosis]; 4. Pregnancy Trimester, First; 5. Pregnancy Trimester, Second; 6. Randomized Controlled Trials as Topic;
MESH terms:
Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes
1. Diabetes, Gestational [*prevention & control]; 2. Preconception Care [*methods]; 3. Secondary Prevention;
MESH terms:
Elective repeat caesarean section versus induction of labour for women with a previous caesarean birth
1. *Cesarean Section, Repeat [adverse effects]; 2. *Elective Surgical Procedures [adverse effects]; 3. *Labor, Induced [adverse effects]; 4. Vaginal Birth after Cesarean;
MESH terms:
Perineal techniques during the second stage of labour for reducing perineal trauma
1. *Labor Stage, Second; 2. Anal Canal [*injuries]; 3. Delivery, Obstetric [*methods]; 4. Episiotomy [adverse effects, statistics & numerical data]; 5. Hot Temperature [*therapeutic use]; 6. Lacerations [*prevention & control]; 7. Massage; 8. Obstetric Labor Complications [*prevention & control]; 9. Perineum [*injuries]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Fetal and umbilical Doppler ultrasound in high‐risk pregnancies
1. Cardiotocography; 2. Cesarean Section [statistics & numerical data]; 3. Fetal Monitoring [*methods]; 4. Labor, Induced [statistics & numerical data]; 5. Perinatal Mortality; 6. *Pregnancy, High-Risk; 7. Randomized Controlled Trials as Topic; 8. Stillbirth [epidemiology]; 9. *Ultrasonography, Prenatal; 10. Umbilical Arteries [*diagnostic imaging, physiopathology]; 11. Umbilical Cord [blood supply, *diagnostic imaging];
MESH terms:
Treating periodontal disease for preventing adverse birth outcomes in pregnant women
1. Gingivitis [*therapy]; 2. Infant, Low Birth Weight; 3. Infant, Small for Gestational Age; 4. Perinatal Mortality; 5. Periodontal Diseases [*therapy]; 6. Pre‐Eclampsia [epidemiology]; 7. Pregnancy Complications [*therapy]; 8. Pregnancy Outcome; 9. Premature Birth [epidemiology, prevention & control]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Methods of term labour induction for women with a previous caesarean section
1. *Vaginal Birth after Cesarean; 2. Dinoprostone [administration & dosage]; 3. Early Termination of Clinical Trials; 4. Labor, Induced [*methods]; 5. Misoprostol [administration & dosage]; 6. Oxytocics [*administration & dosage]; 7. Oxytocin [administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Uterine Rupture [etiology];
MESH terms:
Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy
1. Administration, Intravaginal; 2. Cerclage, Cervical [adverse effects, *methods]; 3. Cesarean Section [statistics & numerical data]; 4. Injections, Intramuscular; 5. Perinatal Death [prevention & control]; 6. Premature Birth [epidemiology, *prevention & control]; 7. Progesterone [administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Stillbirth [epidemiology]; 10. Suture Techniques;
MESH terms:
Patient‐controlled analgesia with remifentanil versus alternative parenteral methods for pain management in labour
1. *Analgesics, Opioid [administration & dosage, adverse effects]; 2. *Piperidines [administration & dosage, adverse effects]; 3. Analgesia, Epidural [adverse effects]; 4. Analgesia, Obstetrical [*methods]; 5. Analgesia, Patient‐Controlled [*methods]; 6. Apnea [chemically induced]; 7. Cesarean Section [statistics & numerical data]; 8. Labor Pain [*drug therapy]; 9. Pain Measurement; 10. Patient Satisfaction; 11. Randomized Controlled Trials as Topic; 12. Remifentanil;
MESH terms:
Pelvimetry for fetal cephalic presentations at or near term for deciding on mode of delivery
1. Apgar Score; 2. Blood Transfusion [statistics & numerical data]; 3. Cesarean Section [statistics & numerical data]; 4. Delivery, Obstetric [*methods]; 5. *Labor Presentation; 6. Pelvimetry [*methods]; 7. Perinatal Mortality; 8. Randomized Controlled Trials as Topic; 9. Surgical Wound Dehiscence [epidemiology]; 10. Surgical Wound Infection [epidemiology]; 11. *Term Birth;
MESH terms:
Fundal pressure during the second stage of labour
1. Apgar Score; 2. Cervix Uteri [injuries]; 3. Cesarean Section [statistics & numerical data]; 4. Delivery, Obstetric [adverse effects, *methods, statistics & numerical data]; 5. Labor Stage, Second [*physiology]; 6. Perineum [injuries]; 7. Pressure; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes
1. *Bed Rest [methods]; 2. *Hospitalization; 3. *Pregnancy, Multiple [statistics & numerical data]; 4. *Pregnancy, Triplet [statistics & numerical data]; 5. *Pregnancy, Twin [statistics & numerical data]; 6. Activities of Daily Living; 7. Birth Weight; 8. Fetal Membranes, Premature Rupture [epidemiology]; 9. Infant, Small for Gestational Age; 10. Perinatal Mortality; 11. Pregnancy Outcome; 12. Randomized Controlled Trials as Topic;
MESH terms:
Iodine supplementation for women during the preconception, pregnancy and postpartum period
1. *Dietary Supplements [adverse effects]; 2. Hyperthyroidism [epidemiology]; 3. Hypothyroidism [epidemiology]; 4. Infant, Newborn, Diseases [epidemiology]; 5. Iodine [*administration & dosage, adverse effects, deficiency]; 6. Perinatal Mortality; 7. Postpartum Period; 8. Preconception Care [*methods]; 9. Pregnancy Complications [epidemiology]; 10. Premature Birth [epidemiology]; 11. Prenatal Care [*methods]; 12. Randomized Controlled Trials as Topic; 13. Thyroid Hormones [blood]; 14. Thyrotropin [blood];
MESH terms:
Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome
1. Cesarean Section [statistics & numerical data]; 2. Chorioamnionitis [epidemiology]; 3. Delivery, Obstetric [*methods]; 4. Fetal Death; 5. *Fetal Membranes, Premature Rupture; 6. Gestational Age; 7. Intensive Care Units, Neonatal [statistics & numerical data]; 8. Labor Onset; 9. Length of Stay [statistics & numerical data]; 10. Perinatal Mortality; 11. Premature Birth; 12. Randomized Controlled Trials as Topic; 13. Respiration, Artificial [statistics & numerical data]; 14. Respiratory Distress Syndrome, Newborn [epidemiology, prevention & control]; 15. Sepsis [epidemiology, prevention & control]; 16. *Watchful Waiting;
MESH terms:
Breastfeeding education and support for women with twins or higher order multiples
1. *Breast Feeding; 2. *Multiple Birth Offspring; 3. Breast Milk Expression; 4. Counseling; 5. House Calls; 6. Mothers [*education]; 7. Randomized Controlled Trials as Topic; 8. Telephone; 9. Twins;
MESH terms:
Psychosocial interventions for supporting women to stop smoking in pregnancy
1. Counseling; 2. Exercise; 3. Feedback, Psychological; 4. Health Education; 5. Infant, Low Birth Weight; 6. Motivation; 7. Obstetric Labor, Premature; 8. Patient Education as Topic; 9. Pregnancy Outcome; 10. *Pregnant Women; 11. Randomized Controlled Trials as Topic; 12. Smoking Cessation [*methods, statistics & numerical data]; 13. Social Support;
MESH terms:
Medical treatments for incomplete miscarriage
1. *Watchful Waiting; 2. Abortifacient Agents, Nonsteroidal [*administration & dosage, adverse effects]; 3. Abortion, Incomplete [*therapy]; 4. Administration, Intravaginal; 5. Administration, Oral; 6. Diarrhea [chemically induced]; 7. Extraction, Obstetrical [*methods]; 8. Gestational Age; 9. Misoprostol [*administration & dosage, adverse effects]; 10. Nausea [chemically induced]; 11. Pregnancy Trimester, First; 12. Randomized Controlled Trials as Topic; 13. Vomiting [chemically induced];
MESH terms:
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
1. *Cesarean Section [statistics & numerical data]; 2. *Hypertension; 3. *Labor, Induced [statistics & numerical data]; 4. *Pregnancy Complications, Cardiovascular; 5. *Watchful Waiting; 6. Delivery, Obstetric; 7. Gestational Age; 8. Infant Mortality; 9. Length of Stay; 10. Maternal Mortality; 11. Pre‐Eclampsia; 12. Randomized Controlled Trials as Topic;
MESH terms:
Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more)
1. *Fetal Membranes, Premature Rupture; 2. *Term Birth; 3. *Watchful Waiting; 4. Cesarean Section [statistics & numerical data]; 5. Labor, Induced [*methods]; 6. Misoprostol [administration & dosage]; 7. Obstetric Labor Complications; 8. Oxytocics [administration & dosage]; 9. Oxytocin [administration & dosage]; 10. Pregnancy Outcome; 11. Prostaglandins [administration & dosage]; 12. Randomized Controlled Trials as Topic; 13. Time Factors;
MESH terms:
Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy
1. Anemia [*prevention & control]; 2. *Anemia, Sickle Cell [complications]; 3. Blood Transfusion [*methods]; 4. Heart Failure [etiology]; 5. Perinatal Mortality; 6. Pregnancy Complications, Hematologic [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Transfusion Reaction;
MESH terms:
Antenatal breastfeeding education for increasing breastfeeding duration
1. *Breast Feeding [statistics & numerical data]; 2. Counseling [methods]; 3. Mothers [*education]; 4. Peer Group; 5. Prenatal Care [*methods]; 6. Randomized Controlled Trials as Topic; 7. Time Factors;
MESH terms:
Nitric oxide donors for cervical ripening and induction of labour
1. *Nitric Oxide Donors; 2. Administration, Intravaginal; 3. Cervical Ripening [*drug effects, physiology]; 4. Dinoprostone; 5. Labor, Induced [*methods]; 6. Misoprostol; 7. Oxytocics; 8. Randomized Controlled Trials as Topic; 9. Urinary Catheterization;
MESH terms:
Interventions for promoting the initiation of breastfeeding
1. Breast Feeding [*psychology, statistics & numerical data]; 2. Counseling [methods]; 3. Health Education [*methods]; 4. Peer Group; 5. Randomized Controlled Trials as Topic;
MESH terms:
Chewing gum for enhancing early recovery of bowel function after caesarean section
1. *Chewing Gum; 2. *Recovery of Function; 3. Cesarean Section [*adverse effects]; 4. Gastrointestinal Motility [*physiology]; 5. Ileus [etiology, *therapy]; 6. Postoperative Complications [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Effect of restricted pacifier use in breastfeeding term infants for increasing duration of breastfeeding
1. *Lactation; 2. *Motivation; 3. Breast Feeding [psychology, *statistics & numerical data]; 4. Pacifiers [adverse effects, *statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Rooming‐in for new mother and infant versus separate care for increasing the duration of breastfeeding
1. *Nurseries, Hospital; 2. Breast Feeding [*statistics & numerical data]; 3. Infant Care [*methods]; 4. Postnatal Care [*methods]; 5. Randomized Controlled Trials as Topic; 6. Rooming‐in Care [*methods]; 7. Time Factors;
MESH terms:
Amnioinfusion for chorioamnionitis
1. *Amniotic Fluid; 2. Anti‐Bacterial Agents [administration & dosage]; 3. Cervix Uteri; 4. Cesarean Section [statistics & numerical data]; 5. Chorioamnionitis [*therapy]; 6. Endometritis [epidemiology]; 7. Infections [epidemiology]; 8. Length of Stay; 9. Perinatal Death;
MESH terms:
Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history
1. Abortion, Habitual [etiology, *prevention & control]; 2. Bromocriptine [*therapeutic use]; 3. Dopamine Agonists [*therapeutic use]; 4. Hyperprolactinemia [complications, *drug therapy]; 5. Live Birth; 6. Randomized Controlled Trials as Topic;
MESH terms:
Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes
1. *Infant, Premature; 2. Cerebral Palsy [etiology]; 3. Cesarean Section [statistics & numerical data]; 4. Delivery, Obstetric [adverse effects, *methods]; 5. Fetal Distress [*complications]; 6. Infant Mortality; 7. Randomized Controlled Trials as Topic; 8. Respiration, Artificial [statistics & numerical data]; 9. Watchful Waiting;
MESH terms:
Sealing procedures for preterm prelabour rupture of membranes
1. Equipment Design; 2. Fetal Membranes, Premature Rupture [*therapy]; 3. Immunologic Factors [*therapeutic use]; 4. Negative-Pressure Wound Therapy [*instrumentation, methods]; 5. *Obstetric Labor, Premature; 6. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for treating hyperemesis gravidarum
1. Acupuncture Therapy [*methods]; 2. Adrenal Cortex Hormones [adverse effects, *therapeutic use]; 3. Antiemetics [adverse effects, *therapeutic use]; 4. Hydrocortisone [therapeutic use]; 5. Hyperemesis Gravidarum [*therapy]; 6. Metoclopramide [adverse effects, therapeutic use]; 7. Ondansetron [adverse effects, therapeutic use]; 8. Placebo Effect; 9. Prednisolone [adverse effects, therapeutic use]; 10. Promethazine [therapeutic use]; 11. Pyridoxine [adverse effects, therapeutic use];
MESH terms:
Oxytocin for preventing postpartum haemorrhage (PPH) in non‐facility birth settings
1. *Rural Health; 2. Community Health Workers [statistics & numerical data]; 3. Ghana; 4. Oxytocics [*administration & dosage]; 5. Oxytocin [*administration & dosage]; 6. Postpartum Hemorrhage [*prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Techniques for assisting difficult delivery at caesarean section
1. *Tocolysis; 2. Birth Injuries [etiology]; 3. Cesarean Section [*methods]; 4. Extraction, Obstetrical [adverse effects, *methods]; 5. Randomized Controlled Trials as Topic; 6. Tocolytic Agents [*administration & dosage];
MESH terms:
Breastfeeding or nipple stimulation for reducing postpartum haemorrhage in the third stage of labour
1. *Breast Feeding; 2. Hematocrit; 3. Incidence; 4. *Labor Stage, Third; 5. Nipples [*physiology]; 6. Oxytocin [*metabolism]; 7. Physical Stimulation [*methods]; 8. Placenta, Retained [epidemiology]; 9. Postpartum Hemorrhage [epidemiology, *prevention & control]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Planned caesarean section for women with a twin pregnancy
1. *Parturition; 2. *Pregnancy Outcome; 3. *Pregnancy, Twin; 4. Cesarean Section [adverse effects, *methods, mortality]; 5. Elective Surgical Procedures [adverse effects, methods, mortality]; 6. Maternal Mortality; 7. Perinatal Mortality; 8. Randomized Controlled Trials as Topic;
MESH terms:
Incentives for increasing prenatal care use by women in order to improve maternal and neonatal outcomes
1. *Motivation; 2. Cesarean Section [statistics & numerical data]; 3. Postnatal Care [standards, statistics & numerical data]; 4. Pregnancy Outcome; 5. Prenatal Care [*psychology, statistics & numerical data]; 6. Quality of Health Care; 7. Randomized Controlled Trials as Topic;
MESH terms:
Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour
1. Bone Diseases, Metabolic [epidemiology]; 2. Fetal Death; 3. Fractures, Bone [epidemiology]; 4. Hypocalcemia [epidemiology]; 5. Infant Death; 6. Injections, Intravenous; 7. Magnesium Sulfate [*administration & dosage, adverse effects]; 8. Obstetric Labor, Premature [*drug therapy]; 9. Perinatal Death; 10. Premature Birth [*prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Tocolysis [*methods]; 13. Tocolytic Agents [*administration & dosage, adverse effects];
MESH terms:
Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy
1. *Pregnancy, Twin; 2. Administration, Oral; 3. Adrenergic beta‐Agonists [*administration & dosage]; 4. Albuterol [administration & dosage]; 5. Fenoterol [administration & dosage]; 6. Fetal Membranes, Premature Rupture [prevention & control]; 7. Gestational Age; 8. Isoxsuprine [administration & dosage]; 9. Premature Birth [*prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Ritodrine [administration & dosage]; 12. Terbutaline [administration & dosage]; 13. Tocolytic Agents [*administration & dosage];
MESH terms:
Health system and community level interventions for improving antenatal care coverage and health outcomes
1. Community Health Services; 2. Infant, Low Birth Weight; 3. Parturition; 4. Patient Acceptance of Health Care [statistics & numerical data]; 5. Perinatal Mortality; 6. Pregnancy Complications [mortality]; 7. Prenatal Care [methods, *statistics & numerical data]; 8. Tetanus Toxoid [administration & dosage];
MESH terms:
Use of biochemical tests of placental function for improving pregnancy outcome
1. *Pregnancy Outcome; 2. Biomarkers [blood]; 3. Infant, Small for Gestational Age; 4. Perinatal Death; 5. Placenta [*physiology]; 6. Placental Function Tests [*methods]; 7. Randomized Controlled Trials as Topic; 8. Stillbirth [epidemiology];
MESH terms:
Nutritional advice for improving outcomes in multiple pregnancies
1. *Weight Gain; 2. Pregnancy, Multiple [*physiology]; 3. Prenatal Nutritional Physiological Phenomena [*physiology];
MESH terms:
Nitroglycerin for management of retained placenta
1. Administration, Sublingual; 2. Headache [chemically induced]; 3. Nitroglycerin [adverse effects, *therapeutic use]; 4. Oxytocics [*therapeutic use]; 5. Oxytocin [therapeutic use]; 6. Placenta, Retained [*drug therapy]; 7. Postpartum Hemorrhage; 8. Randomized Controlled Trials as Topic;
MESH terms:
Specialised antenatal clinics for women with a multiple pregnancy for improving maternal and infant outcomes
1. *Infant Welfare; 2. *Maternal Welfare; 3. *Pregnancy Outcome; 4. *Pregnancy, Multiple; 5. Cesarean Section [statistics & numerical data]; 6. Perinatal Mortality; 7. Pregnancy, Twin; 8. Prenatal Care [methods, *standards]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Ethanol for preventing preterm birth in threatened preterm labor
1. *Obstetric Labor, Premature; 2. Ethanol [*therapeutic use]; 3. Pregnancy Outcome; 4. Premature Birth [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Tocolytic Agents [*therapeutic use];
MESH terms:
Reduction of the number of fetuses for women with a multiple pregnancy
1. *Pregnancy, Multiple; 2. Pregnancy Reduction, Multifetal [*adverse effects, *psychology];
MESH terms:
Risk‐scoring systems for predicting preterm birth with the aim of reducing associated adverse outcomes
1. *Pregnancy, High‐Risk; 2. Premature Birth [*diagnosis, prevention & control]; 3. Risk Assessment [methods];
MESH terms:
Intermittent oral iron supplementation during pregnancy
1. Administration, Oral; 2. Anemia, Iron-Deficiency [blood, *prevention & control]; 3. Developing Countries; 4. Dietary Supplements [*adverse effects]; 5. Drug Administration Schedule; 6. Drug Combinations; 7. Folic Acid [administration & dosage]; 8. Hemoglobin A [metabolism]; 9. Infant, Low Birth Weight; 10. Iron [*administration & dosage, adverse effects]; 11. Iron, Dietary [*administration & dosage]; 12. Pregnancy Complications, Hematologic [blood, *prevention & control]; 13. Premature Birth; 14. Randomized Controlled Trials as Topic; 15. Vitamins [administration & dosage];
MESH terms:
Fetal movement counting for assessment of fetal wellbeing
1. Fetal Monitoring [*methods]; 2. Fetal Movement [*physiology]; 3. Pregnancy Outcome; 4. Randomized Controlled Trials as Topic; 5. Time Factors;
MESH terms:
Antenatal cardiotocography for fetal assessment
1. Cardiotocography [*methods]; 2. Diagnosis, Computer‐Assisted [methods]; 3. Perinatal Mortality; 4. Randomized Controlled Trials as Topic;
MESH terms:
Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth
1. Abdomen; 2. Fetal Growth Retardation [*diagnosis, diagnostic imaging]; 3. Palpation [*methods]; 4. Pubic Symphysis [*anatomy & histology]; 5. Randomized Controlled Trials as Topic; 6. Ultrasonography, Prenatal; 7. Uterus [*anatomy & histology];
MESH terms:
Anti‐D administration in pregnancy for preventing Rhesus alloimmunisation
1. Immunologic Factors [*therapeutic use]; 2. Pregnancy Trimester, Third; 3. Randomized Controlled Trials as Topic; 4. Rh Isoimmunization [*prevention & control]; 5. Rho(D) Immune Globulin [*therapeutic use];
MESH terms:
Treatments for breast abscesses in breastfeeding women
1. *Breast Feeding; 2. Abscess [etiology, *therapy]; 3. Biopsy, Fine‐Needle [methods]; 4. Breast Diseases [etiology, *therapy]; 5. Cephalosporins [therapeutic use]; 6. Drainage [methods]; 7. Mastitis [etiology, therapy]; 8. Randomized Controlled Trials as Topic; 9. Treatment Failure; 10. Ultrasonography, Interventional;
MESH terms:
High feedback versus low feedback of prenatal ultrasound for reducing maternal anxiety and improving maternal health behaviour in pregnancy
1. Alcohol Drinking [prevention & control]; 2. Anxiety [*prevention & control]; 3. Communication; 4. *Feedback, Psychological; 5. *Health Behavior; 6. Maternal Behavior [*psychology]; 7. Randomized Controlled Trials as Topic; 8. Smoking Prevention; 9. Ultrasonography, Prenatal [*psychology];
MESH terms:
Education for contraceptive use by women after childbirth
1. *Contraception; 2. *Patient Education as Topic; 3. *Postpartum Period; 4. Family Planning Services [*education]; 5. Program Evaluation; 6. Randomized Controlled Trials as Topic;
MESH terms:
Expedited versus conservative approaches for vaginal delivery in breech presentation
1. *Breech Presentation; 2. Delivery, Obstetric [*methods];
MESH terms:
Planned caesarean section for term breech delivery
1. *Breech Presentation [mortality]; 2. *Cesarean Section [adverse effects, statistics & numerical data]; 3. *Elective Surgical Procedures [adverse effects, statistics & numerical data]; 4. Birth Injuries [prevention & control]; 5. Brachial Plexus Neuropathies [prevention & control]; 6. Odds Ratio; 7. Randomized Controlled Trials as Topic;
MESH terms:
Ultrasound for fetal assessment in early pregnancy
1. *Pregnancy, Multiple; 2. Congenital Abnormalities [*diagnostic imaging]; 3. Fetal Monitoring [*methods]; 4. Gestational Age; 5. Perinatal Mortality; 6. Pregnancy Trimester, First; 7. Pregnancy Trimester, Second; 8. Ultrasonography, Prenatal [*methods];
MESH terms:
Routine ultrasound in late pregnancy (after 24 weeks' gestation)
1. *Pregnancy Outcome; 2. *Ultrasonography, Prenatal; 3. Perinatal Mortality; 4. Pregnancy Trimester, Second; 5. Pregnancy Trimester, Third; 6. Premature Birth [epidemiology]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Tranexamic acid for preventing postpartum haemorrhage
1. Antifibrinolytic Agents [*administration & dosage]; 2. Injections, Intravenous; 3. Postpartum Hemorrhage [*prevention & control]; 4. Randomized Controlled Trials as Topic; 5. Tranexamic Acid [*administration & dosage];
MESH terms:
Diet or exercise, or both, for preventing excessive weight gain in pregnancy
1. *Diet; 2. *Exercise; 3. *Weight Gain; 4. Counseling; 5. Overweight [complications, *prevention & control]; 6. Pregnancy Complications [*prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes
1. *Coffee; 2. Birth Weight [*drug effects]; 3. Caffeine [administration & dosage, *pharmacology]; 4. Central Nervous System Stimulants [administration & dosage, *pharmacology]; 5. Infant, Small for Gestational Age; 6. Pregnancy [*drug effects]; 7. Pregnancy Outcome; 8. Premature Birth [etiology]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Planned early delivery versus expectant management for monoamniotic twins
1. *Pregnancy, Twin; 2. *Twins, Monozygotic; 3. *Watchful Waiting; 4. Delivery, Obstetric [*methods];
MESH terms:
Fetal and umbilical Doppler ultrasound in normal pregnancy
1. *Ultrasonography, Doppler; 2. Perinatal Mortality; 3. Pregnancy Outcome; 4. Randomized Controlled Trials as Topic; 5. Ultrasonography, Prenatal [*methods]; 6. Umbilical Arteries [*diagnostic imaging]; 7. Uterine Artery [diagnostic imaging];
MESH terms:
External cephalic version for breech presentation at term
1. *Breech Presentation; 2. *Term Birth; 3. Cesarean Section; 4. Pregnancy Outcome; 5. Randomized Controlled Trials as Topic; 6. Version, Fetal [*methods];
MESH terms:
Bed rest in singleton pregnancies for preventing preterm birth
1. *Bed Rest [adverse effects]; 2. *Pregnancy, High‐Risk; 3. Premature Birth [*prevention & control]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Oral analgesia for relieving post‐caesarean pain
1. Administration, Oral; 2. Analgesia [*methods]; 3. Analgesics, Non‐Narcotic [administration & dosage]; 4. Analgesics, Opioid [*administration & dosage]; 5. Cesarean Section [*adverse effects]; 6. Drug Therapy, Combination [methods]; 7. Pain, Postoperative [*drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Community‐based intervention packages for reducing maternal and neonatal morbidity and mortality and improving neonatal outcomes
1. *Infant Mortality [trends]; 2. *Maternal Mortality [trends]; 3. *Perinatal Mortality [trends]; 4. Cause of Death; 5. Community Health Services [*organization & administration, statistics & numerical data]; 6. Maternal Health Services [organization & administration, statistics & numerical data]; 7. Morbidity; 8. Randomized Controlled Trials as Topic;
MESH terms:
Combined hormonal versus nonhormonal versus progestin‐only contraception in lactation
1. Breast Feeding [*statistics & numerical data]; 2. Child Development [drug effects]; 3. Contraception [*methods]; 4. Contraceptives, Oral, Combined [*pharmacology]; 5. Contraceptives, Oral, Hormonal [pharmacology]; 6. Desogestrel [pharmacology]; 7. Lactation [*drug effects]; 8. Levonorgestrel [pharmacology]; 9. Milk, Human [*drug effects]; 10. Progestins [*pharmacology]; 11. Randomized Controlled Trials as Topic;